NASDAQ: RNAZTranscode Therapeutics Inc Stock
$11.36-0.31 (-2.66%)
Updated Sep 17, 2025
RNAZ Price
$11.36
Fair Value Price
$16.21
Market Cap
$9.47M
52 Week Low
$6.15
52 Week High
$739.20
P/E
0x
P/B
1.54x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$24.60M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.35
Operating Cash Flow
-$14M
Beta
1.34
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RNAZ Overview
TransCode Therapeutics Incorporated is a biopharmaceutical company that develops drugs and diagnostics for treating and identifying metastatic disease. The company's lead therapeutic candidate is TTX-MC138, a preclinical stage product for the treatment of metastatic cancer. TransCode Therapeutics was incorporated in 2016 and is headquartered in Boston, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RNAZ's potential to beat the market
- RNAZ doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RNAZ
RankedUnranked of 479
RankedUnranked of 479
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.05 | A | |
| $7.70 | A | |
| $34.22 | A |
Be the first to know about important RNAZ news, forecast changes, insider trades & much more!
RNAZ News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RNAZ scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RNAZ ($11.36) is undervalued by 29.92% relative to our estimate of its Fair Value price of $16.21 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
RNAZ ($11.36) is significantly undervalued by 29.92% relative to our estimate of its Fair Value price of $16.21 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
RNAZ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RNAZ due diligence checks available for Premium users.
Valuation
RNAZ fair value
Fair Value of RNAZ stock based on Discounted Cash Flow (DCF)
Price
$11.36
Fair Value
$16.21
Undervalued by
29.92%
RNAZ ($11.36) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RNAZ ($11.36) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RNAZ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RNAZ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-97.28x
Market
37.36x
RNAZ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.54x
Industry
4.69x
RNAZ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RNAZ's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.3M
Profit Margin
0%
RNAZ's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$8.3M
Liabilities
$2.1M
Debt to equity
0.35
RNAZ's short-term assets ($8.24M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RNAZ's short-term assets ($8.24M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RNAZ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.2M
Investing
$0.0
Financing
$0.0
RNAZ's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RNAZ vs Biotech Stocks
Transcode Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.